TrialThe European journal of health economics : HEPAC : health economics in prevention and care2020

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.

M Campioni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.